ML-004 (IR)/(ER) tablet
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Jun 1, 2023 → Dec 1, 2027
NCT ID
NCT05889273About ML-004 (IR)/(ER) tablet
ML-004 (IR)/(ER) tablet is a phase 2 stage product being developed by MapLight Therapeutics for Autism Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05889273. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05889273 | Phase 2 | Recruiting |
Competing Products
20 competing products in Autism Spectrum Disorder